The Use of N-Terminal-Pro-BNP in Preterm Infants
Author(s) -
Afif ElKhuffash,
Eleanor J. Molloy
Publication year - 2009
Publication title -
international journal of pediatrics
Language(s) - English
Resource type - Journals
eISSN - 1687-9759
pISSN - 1687-9740
DOI - 10.1155/2009/175216
Subject(s) - medicine , ductus arteriosus , natriuretic peptide , population , congenital diaphragmatic hernia , cardiology , pediatrics , heart failure , pregnancy , fetus , environmental health , biology , genetics
The use of natriuretic peptides in the neonatal population is emerging. B-type Natriuretic Peptide (BNP) and N-terminal-Pro-BNP (NTpBNP) are used in the adult population to assess myocardial function and volume loading. Their role in prognosis following cardiac surgery has also been identified. In preterm infants NTpBNP is becoming increasingly recognised as a potential screening tool for patent ductus arteriosus (PDA), and a marker for myocardial performance. In addition, NTpBNP may provide prognostic information in preterm infants and term infants with congenital diaphragmatic hernia (CDH). In this paper, the role of NTpBNP in the preterm population will be discussed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom